TY  - CHAP
M1  - Book, Section
TI  - Adoptive T Cell Therapy for Haematological Malignancies
A1  - Benjamin, Reuben
A1  - Graham, Charlotte
A2  - Board, Ruth E.
A2  - Nathan, Paul
A2  - Newsom-Davis, Tom
A2  - Papa, Sophie
A2  - Johnson, Peter
Y1  - 2019
N1  - 
T2  - Problem Solving in Cancer Immunotherapy
AB  - The  anticancer  potential  of  the  immune  system  has  long  been  recognized  in  haematological  malignancies,  with  allogeneic  stem  cell  transplantation  and  donor  lymphocyte  infusions  now  established  as  standards  of  care  for  acute  myeloid  leukaemia  (AML),  acute  lymphoblastic  leukaemia  (ALL)  and  some  types  of  lymphomas.  In  addition,  immunomodulatory  drugs  and  monoclonal  antibodies  that  trigger  antibody-dependent  cell-mediated  cytotoxicity  have  been  shown  to  be  effective  treatments  for  multiple  myeloma  and  B  cell  lymphomas  (e.g.  B  cell  non-Hodgkin  lymphoma  [B-NHL]).  The  accessibility  of  bone  marrow  and  lymph  nodes  (the  predominant  sites  of  haematological  tumours)  to  circulating  immune  cells,  as  well  as  their  susceptibility  to  immune  cell-mediated  killing,  makes  them  an  obvious  target  for  adoptive  T  cell  therapy  (ACT).  It  was,  however,  the  discovery  that  T  lymphocytes  could  be  retargeted  to  tumour  cells,  independently  of  the  major  histocompatibility  complex  (MHC),  using  chimeric  antigen  receptors  (CARs)  that  fuelled  interest  in  the  field  of  ACT  for  haematological  malignancies.  
SN  - 
PB  - EBN Health
CY  - New York, NY
Y2  - 2021/03/05
UR  - hemonc.mhmedical.com/content.aspx?aid=1160632881
ER  -